← Back to Analyst Consensus 
SRPT Hold
Sarepta Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 32
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 4 reiterations from 4 firms
Next Earnings
Nov 5, 2026 (10 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 8, 2026 | RBC Capital | maintain | Sector Perform → Sector Perform | — | 55% |
| Oct 5, 2026 | HC Wainwright & Co. | reiterate | Sell → Sell | — | 44% |
| Sep 30, 2026 | JP Morgan | maintain | Neutral → Neutral | — | 55% |
| Sep 28, 2026 | Needham | reiterate | Underperform → Underperform | — | 50% |
| Jul 9, 2026 | Piper Sandler | maintain | Neutral → Neutral | — | 54% |
| Jul 9, 2026 | Wolfe Research | upgrade | Peer Perform → Outperform | — | 54% |
| Apr 16, 2026 | HC Wainwright & Co. | reiterate | Sell → Sell | — | 44% |
| Mar 26, 2026 | Citigroup | maintain | Sell → Sell | — | 54% |
| Mar 26, 2026 | Needham | reiterate | Underperform → Underperform | — | 50% |
| Mar 19, 2026 | Oppenheimer | reiterate | Outperform → Outperform | — | 52% |
| Mar 13, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Mar 10, 2026 | Citigroup | maintain | Sell → Sell | — | 54% |
| Mar 2, 2026 | HC Wainwright & Co. | reiterate | Sell → Sell | — | 44% |
| Feb 27, 2026 | Wells Fargo | maintain | Overweight → Overweight | $38 | 54% |
| Jan 27, 2026 | HC Wainwright & Co. | reiterate | Sell → Sell | $5 | 44% |
| Jan 23, 2026 | Wedbush | maintain | Outperform → Outperform | $34 | 58% |
| Jan 14, 2026 | HC Wainwright & Co. | reiterate | Sell → Sell | $5 | 44% |
| Dec 9, 2025 | Wedbush | initiate | — → Outperform | $32 | 58% |
| Nov 5, 2025 | Barclays | maintain | Equal-Weight → Equal-Weight | $20 | 53% |
| Nov 5, 2025 | Wells Fargo | maintain | Overweight → Overweight | $45 | 54% |
| Nov 5, 2025 | Guggenheim | maintain | Buy → Buy | $19 | 52% |
| Nov 5, 2025 | Mizuho | upgrade | Neutral → Outperform | $26 | 52% |
| Nov 4, 2025 | Baird | maintain | Neutral → Neutral | $15 | 55% |
| Oct 30, 2025 | Piper Sandler | maintain | Neutral → Neutral | $16 | 54% |
| Sep 22, 2025 | BMO Capital | upgrade | Market Perform → Outperform | $50 | 53% |
| Sep 15, 2025 | Guggenheim | reiterate | Buy → Buy | $22 | 52% |
| Sep 9, 2025 | Leerink Partners | maintain | Market Perform → Market Perform | $15 | 50% |
| Aug 25, 2025 | HC Wainwright & Co. | reiterate | Sell → Sell | $5 | 44% |
| Aug 21, 2025 | B of A Securities | maintain | Underperform → Underperform | $16 | 53% |
| Aug 20, 2025 | B of A Securities | maintain | Underperform → Underperform | $17 | 53% |
| Aug 15, 2025 | Deutsche Bank | maintain | Sell → Sell | $12 | 57% |
| Aug 7, 2025 | Goldman Sachs | maintain | Neutral → Neutral | $19 | 54% |
| Aug 7, 2025 | Wells Fargo | maintain | Overweight → Overweight | $50 | 54% |
| Jul 30, 2025 | Barclays | upgrade | Underweight → Equal-Weight | $22 | 53% |
| Jul 29, 2025 | Barclays | upgrade | Underweight → Equal-Weight | $22 | 53% |
| Jul 29, 2025 | Bernstein | initiate | — → Market Perform | $13 | 52% |
| Jul 29, 2025 | BMO Capital | maintain | Market Perform → Market Perform | $50 | 53% |
| Jul 29, 2025 | Piper Sandler | maintain | Neutral → Neutral | $15 | 54% |
| Jul 29, 2025 | Morgan Stanley | maintain | Equal-Weight → Equal-Weight | $20 | 54% |
| Jul 29, 2025 | Oppenheimer | upgrade | Perform → Outperform | $37 | 52% |
| Jul 29, 2025 | JP Morgan | upgrade | Underweight → Neutral | $24 | 55% |
| Jul 29, 2025 | Needham | reiterate | Underperform → Underperform | $0 | 50% |
| Jul 28, 2025 | Needham | reiterate | Underperform → Underperform | $0 | 50% |
| Jul 27, 2025 | Barclays | downgrade | Equal-Weight → Underweight | $10 | 53% |
| Jul 25, 2025 | Deutsche Bank | maintain | Sell → Sell | $6 | 57% |
| Jul 25, 2025 | JP Morgan | downgrade | Neutral → Underweight | $0 | 55% |
| Jul 24, 2025 | Jefferies | maintain | Buy → Buy | $35 | 52% |
| Jul 24, 2025 | Wells Fargo | maintain | Overweight → Overweight | $48 | 54% |
| Jul 24, 2025 | Citigroup | initiate | — → Sell | $7 | 54% |
| Jul 23, 2025 | B of A Securities | downgrade | Neutral → Underperform | $10 | 53% |
Price Target Trend
Jun 13, 2026 Oct 26, 2026
EPS Estimates
+1y —
0q —
+1q —
0y —
Cross-Platform Signals
No cross-platform signals in the last 90 days